TY - JOUR
T1 - Systemic mastocytosis, version 2.2019 clinical practice guidelines in oncology
AU - Gotlib, Jason
AU - Gerds, Aaron T.
AU - Bose, Prithviraj
AU - Castells, Mariana C.
AU - Deininger, Michael W.
AU - Gojo, Ivana
AU - Gundabolu, Krishna
AU - Hobbs, Gabriela
AU - Jamieson, Catriona
AU - McMahon, Brandon
AU - Mohan, Sanjay R.
AU - Oehler, Vivian
AU - Oh, Stephen
AU - Padron, Eric
AU - Pancari, Philip
AU - Papadantonakis, Nikolaos
AU - Pardanani, Animesh
AU - Podoltsev, Nikolai
AU - Rampal, Raajit
AU - Ranheim, Erik
AU - Rein, Lindsay
AU - Snyder, David S.
AU - Stein, Brady L.
AU - Talpaz, Moshe
AU - Thota, Swapna
AU - Wadleigh, Martha
AU - Walsh, Katherine
AU - Bergman, Mary Anne
AU - Sundar, Hema
N1 - Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2018, All rights reserved.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.
AB - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.
UR - http://www.scopus.com/inward/record.url?scp=85058725553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058725553&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0088
DO - 10.6004/jnccn.2018.0088
M3 - Article
C2 - 30545997
AN - SCOPUS:85058725553
SN - 1540-1405
VL - 16
SP - 1500
EP - 1537
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -